Top 15 Companies in Global Pemphigus Vulgaris Market: Industry Intelligence Report by Spherical Insights (2026–2035)

Description

According to a research report published by Spherical Insights & Consulting, the global pemphigus vulgaris market size is projected to grow from USD 506.50 Million in 2025 to USD 1121.3 Million by 2035, at a CAGR of 8.27% during the forecast period 2026–2035. The global pemphigus vulgaris market is driven by the global Pemphigus Vulgaris market is driven by rising autoimmune disease prevalence, improved diagnostic capabilities, increasing awareness, and advancements in biologics and targeted therapies. Expanding healthcare access, ongoing clinical research, and growing adoption of immunosuppressants and monoclonal antibodies further support market growth across developed and emerging regions.

 

Introduction

Pemphigus vulgaris market refers to the diagnosis and treatment of a rare, chronic autoimmune disease characterized by painful blisters and sores on the skin and mucous membranes (often starting in the mouth). It occurs when the immune system mistakenly attacks proteins that hold skin cells together, causing them to separate and form blisters. Despite its rarity, the disease presents a significant clinical burden due to chronic progression and potential complications. Government-backed and institutional data highlight its low but impactful prevalence. According to the National Institutes of Health, pemphigus vulgaris is a rare disorder, while epidemiological studies report a global incidence of approximately 2.8 cases per million people annually, with higher rates observed in regions such as South Asia. Market growth is driven by improved diagnostic awareness, rising autoimmune disease incidence, and increased adoption of corticosteroids and biologics. Opportunities exist in targeted therapies and emerging markets with unmet needs. Recent innovations include monoclonal antibody therapies and enhanced diagnostic tools enabling earlier detection and improved disease management outcomes globally.

 

News:

• In June 2024, Rituximab was introduced under a national reimbursement program in Romania, improving patient access for moderate-to-severe cases and signaling broader adoption of biologics in emerging markets.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Pemphigus Vulgaris Market.

 

Market Segmentation

Global Pemphigus Vulgaris Market Size, Share, and, By Treatment Type (Corticosteroids, Immunosuppressants, Biologics, and Others), By Route of Administration (Oral, Injectable, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Hospitals, Specialty Clinics, and Homecare Settings), By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa), Analysis and Forecast 2026 – 2035.

 

Global Pemphigus Vulgaris Market Size & Statistics

• The market size for Global Pemphigus Vulgaris was estimated to be worth USD 506.50 Million in 2025.
• The market is going to expand at a CAGR of 8.27% between 2026 and 2035.
• The Global Pemphigus Vulgaris market size is anticipated to reach USD 1121.3 Million by 2035.
• North America is expected to generate the largest revenue during the forecast period in the Global Pemphigus Vulgaris market
• Asia Pacific is expected to grow at the fastest rate during the forecast period in the Global Pemphigus Vulgaris market.

 

Regional growth and demand                                    

Asia Pacific is expected to grow at the fastest rate during the forecast period in the global pemphigus vulgaris market. Asia Pacific is expected to grow at the fastest rate due to improving healthcare infrastructure, rising awareness of rare autoimmune diseases such as Pemphigus Vulgaris, and expanding access to advanced therapies. Increasing government healthcare spending and a large patient pool further support rapid market expansion across countries such as India and China.

 

North America is expected to generate the largest revenue during the forecast period in the global pemphigus vulgaris market. North America is expected to generate the highest revenue due to well-established healthcare systems, early adoption of biologic therapies, and strong presence of key pharmaceutical companies. Favorable reimbursement frameworks, higher diagnosis rates, and continuous research activities contribute to sustained market leadership in the region.

 

 

Top 10 Trends in the Global Pemphigus Vulgaris Market

• Increasing Adoption of Biologic Therapies
• Rising Focus on Targeted and Precision Medicine
• Growth In Biosimilar Development
• Advancements In Diagnostic Technologies
• Expanding Clinical Research and Trials
• Improved Access to Treatment in Emerging Markets
• Growing Awareness of Rare Autoimmune Diseases
• Integration Of Digital Health and Teledermatology
• Strategic Collaborations and Partnerships
• Supportive Regulatory and Reimbursement Frameworks

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Pemphigus Vulgaris Market.

 

1. Increasing Adoption of Biologic Therapies

The increasing adoption of biologic therapies represents a significant trend in the global pemphigus vulgaris market. Biologics, particularly monoclonal antibodies such as rituximab, have demonstrated improved efficacy and safety compared to conventional corticosteroids and immunosuppressants. These therapies target specific immune pathways, reducing disease severity and relapse rates. Healthcare providers are increasingly favoring biologics due to their ability to provide long-term disease control. Additionally, regulatory approvals and inclusion in treatment guidelines have accelerated their uptake. As more biologic options become available and affordability improves, their adoption is expected to expand across both developed and emerging healthcare markets globally.

 

2. Rising Focus on Targeted and Precision Medicine

The rising focus on targeted and precision medicine is transforming the treatment landscape of pemphigus vulgaris. Advances in immunology and molecular biology have enabled the development of therapies tailored to specific disease mechanisms and patient profiles. Precision medicine approaches aim to minimize adverse effects while maximizing therapeutic efficacy by identifying biomarkers and patient-specific characteristics. This trend is supported by growing investments in research and development, as well as increasing collaboration between academic institutions and pharmaceutical companies. The shift toward individualized treatment strategies is expected to improve clinical outcomes and drive innovation, positioning precision medicine as a key growth driver in the global market.

 

3. Growth in Biosimilar Development

The growth in biosimilar development is emerging as a critical trend in the pemphigus vulgaris market. Biosimilars offer cost-effective alternatives to established biologic therapies, particularly monoclonal antibodies, thereby improving treatment accessibility. As patents for leading biologics expire, pharmaceutical companies are increasingly investing in biosimilar production to capture market share. Regulatory agencies are also streamlining approval pathways to encourage competition and affordability. The availability of biosimilars is expected to reduce overall treatment costs and expand patient access, especially in price-sensitive markets. This trend supports broader adoption of advanced therapies and contributes to the overall growth and competitiveness of the market.

 

4. Advancements in Diagnostic Technologies

Advancements in diagnostic technologies are significantly enhancing the early detection and management of pemphigus vulgaris. Techniques such as enzyme-linked immunosorbent assay and direct immunofluorescence have improved diagnostic accuracy and reduced the likelihood of misdiagnosis. Early and precise diagnosis enables timely initiation of appropriate therapies, thereby improving patient outcomes and reducing disease complications. Furthermore, ongoing research is focused on identifying novel biomarkers that can facilitate disease monitoring and predict treatment response. The integration of advanced diagnostic tools into clinical practice is strengthening disease management frameworks and supporting the overall growth of the market by increasing the diagnosed patient population.

 

5. Expanding Clinical Research and Trials

Expanding clinical research and trials are playing a vital role in advancing the pemphigus vulgaris market. Pharmaceutical companies and research institutions are actively conducting studies to evaluate the safety and efficacy of novel therapeutic agents, including next-generation biologics and combination therapies. These trials are essential for gaining regulatory approvals and expanding treatment options. Increased funding from the public and private sectors is further accelerating research activities. Additionally, global collaboration in clinical research is enhancing knowledge sharing and innovation. The continuous pipeline development is expected to introduce more effective and safer therapies, thereby driving long-term market growth and improving patient care outcomes.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the global pemphigus vulgaris market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Top 15 Companies Leading the Global Pemphigus Vulgaris Market

1. Genentech
2. Sanofi S.A.
3. Amgen Inc.
4. Pfizer Inc.
5. Novartis AG
6. GlaxoSmithKline plc
7. AstraZeneca
8. AbbVie Inc.
9. Regeneron Pharmaceuticals Inc.
10. Johnson & Johnson Services, Inc.
11. Argenx SE (strong relevance
12. Cabaletta Bio Inc.
13. HanAll Biopharma Co. Ltd.
14. Daewoong Pharmaceutical Co. Ltd.
15. Incyte Corporation

 

1. Genentech

Headquarters: South San Francisco, California, USA

Genentech, active in over 50 countries through its parent network, is a leading biotechnology company and a subsidiary of F. Hoffmann-La Roche Ltd. The company plays a pivotal role in the treatment of Pemphigus Vulgaris through biologic therapies such as rituximab. Genentech focuses on developing targeted and innovative medicines that address complex immune-mediated conditions. Its strong research foundation and integration with Roche’s global infrastructure enable widespread accessibility of advanced therapies. By emphasizing precision medicine and biologics, Genentech continues to contribute significantly to advancements in autoimmune disease management across global markets.

 

2. Sanofi S.A.

Headquarters: Paris, France

Sanofi S.A., active in over 90 countries, is a major pharmaceutical company with a strong focus on immunology and rare diseases. The company is actively involved in developing advanced therapies targeting autoimmune conditions, including pemphigus vulgaris. Sanofi’s strategy emphasizes innovation through biologics and specialty care, supported by strategic acquisitions and collaborations. Its expanding pipeline in immunology and commitment to addressing unmet medical needs strengthen its global market presence. By leveraging its research expertise and broad geographic footprint, Sanofi continues to enhance treatment accessibility and contribute to the evolution of targeted therapies in the autoimmune disease segment.

 

3. Amgen Inc.

Headquarters: Thousand Oaks, California, USA

Amgen Inc., active in over 100 countries, is a leading biotechnology company specializing in biologic therapies for chronic and autoimmune diseases. The company plays a significant role in the global market through its expertise in monoclonal antibodies and targeted treatments. Amgen’s focus on innovation and advanced biologics supports the development of therapies that address complex immune-mediated conditions, including pemphigus vulgaris. Its strong research infrastructure and global commercialization capabilities enable widespread access to its therapies. By continuously investing in biotechnology advancements, Amgen strengthens its position in the evolving autoimmune therapeutics landscape worldwide.

 

4. Pfizer Inc.

Headquarters: New York City, New York, USA

Pfizer Inc., active in over 125 countries, is a global pharmaceutical leader with a diverse portfolio spanning immunology and specialty care. The company contributes to the pemphigus vulgaris market through immunosuppressive therapies and ongoing research into novel treatment approaches. Pfizer’s strong global distribution network and focus on innovation enable it to address complex autoimmune conditions effectively. Its investment in research and development, combined with strategic partnerships, supports the advancement of new therapies. With a well-established presence across developed and emerging markets, Pfizer continues to play a critical role in expanding access to autoimmune disease treatments globally.

 

5. Novartis AG

Headquarters: Basel, Switzerland

Novartis AG, active in over 140 countries, is a prominent pharmaceutical company with extensive involvement in immunology and dermatology. The company is engaged in developing innovative therapies targeting autoimmune disorders, including pemphigus vulgaris. Novartis emphasizes advanced biologics and precision medicine to improve treatment outcomes and patient quality of life. Its strong global footprint, supported by robust research and development capabilities, enables the delivery of cutting-edge therapies across multiple regions. By focusing on innovation and patient-centric solutions, Novartis continues to reinforce its leadership position in the global autoimmune disease treatment market.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Pemphigus Vulgaris Market.

 

Are you ready to discover more about the global pemphigus vulgaris market?

The report provides an in-depth analysis of the leading companies operating in the global pemphigus vulgaris market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Company Profiles

1. Genentech

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisitions
• SWOT Analysis

2. Sanofi S.A.
3. Amgen Inc.
4. Pfizer Inc.
5. Novartis AG
6. GlaxoSmithKline plc
7. AstraZeneca
8. AbbVie Inc
9. Others.

 

Conclusion

The global Pemphigus Vulgaris market is positioned for steady growth, driven by increasing awareness of rare autoimmune disorders, advancements in biologic therapies, and improved diagnostic capabilities. The shift toward targeted and precision medicine, along with expanding clinical research, is reshaping treatment approaches and enhancing patient outcomes. Additionally, growing healthcare access in emerging regions and supportive regulatory frameworks are further strengthening market expansion. Leading companies such as Genentech, Sanofi S.A., and Novartis AG continue to drive innovation and competitive dynamics. Overall, the market presents significant opportunities for stakeholders focused on advanced therapeutics and unmet medical needs.

 

Our Reports:

Australia Commercial Vacuum Cleaner Market Size, Demand to 2035
Europe Ethanol Derivatives Market Size, Scope, Growth to 2035
India Earphones and Headphones Market Size, Forecast to 2035
Brazil Automated External Defibrillator Market Size, Forecast to 2035

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Pemphigus Vulgaris Market.

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter